Allogeneic peripheral blood stem-cell transplantation and long-term survival outcomes - A retrospective observational study

Yıl 2023, Cilt: 40 Sayı: 3, 493 - 496, 30.09.2023

Mukesh Kumar Sandeep Jasuja Sajna Choudhary Aashish Dayma Deepak Saknani Krutika Kurhade Linu Hooda Himanshu Batra

Öz

Allogeneic hematopoietic stem cell transplantation (allo-HCT) has been extensively investigated as a potentially curative treatment option for hematological malignancies and other cancers. The current study aimed to investigate the long-term survival outcomes after allo-HCT. We retrospectively analyzed the long-term survival outcomes of patients who received allo-HCT from April 2015 to March 2021 at the Department of Haematology, SMS Hospital for different malignancies. Data from 51 patients with a mean age of 18.7 ±10.79 years who underwent peripheral blood allo-HCT as their first transplant were included for analysis. The average follow-up period was 30 months with a mortality rate of 23.52% (n=12). Overall, 39 patients were still alive and complete response was observed in 36 (92.3%) of patients. In summary, this retrospective study evidenced that peripheral blood (PB) derived allo-HCT has some survival advantages and can be successfully performed with the appropriate conditioning regimen and graft versus host disease (GVHD) prophylaxis.

Anahtar Kelimeler

Allogeneic transplantation, peripheral blood stem-cell transplantation, conditioning regimen, retrospective observational study, survival outcomes.

Kaynakça

• 1. De Moraes Hungria VT, Chiattone C, Pavlovsky M, Abenoza LM, Agreda GP, Armenta J, et al. Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study. J Glob Oncol [Internet]. 2019 [cited 2022 Aug 3];5(5):1–19. Available from: https://pubmed.ncbi.nlm.nih.gov/31774711/
• 2. An W, Liu Z, Liu J, Xia Y, Hu K, Yu J, et al. Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies. Biomed Res Int. 2020;2020.
• 3. Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, et al. Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant [Internet]. 2015 Nov 1 [cited 2022 Aug 3];21(11):1863–9. Available from: https://pubmed.ncbi.nlm.nih.gov/26256941/
• 4. Selection of Autologous or Allogeneic Transplantation - Holland-Frei Cancer Medicine - NCBI Bookshelf [Internet]. [cited 2022 Aug 3]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK12844/
• 5. Crowther M, Avenell A, Culligan DJ. Systematic review and meta-analyses of studies of glutamine supplementation in haematopoietic stem cell transplantation. Bone Marrow Transplant [Internet]. 2009 [cited 2022 Aug 3];44(7):413–25. Available from: https://pubmed.ncbi.nlm.nih.gov/19270730/
• 6. Wildes TM, Stirewalt DL, Medeiros B, Hurria A. Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic. J Natl Compr Canc Netw [Internet]. 2014 Jan 1 [cited 2022 Aug 3];12(1):128–36. Available from: https://pubmed.ncbi.nlm.nih.gov/24453296/
• 7. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol [Internet]. 2011 Jun 1 [cited 2022 Aug 3];29(16):2230–9. Available from: https://pubmed.ncbi.nlm.nih.gov/21464398/
• 8. Du J, Yu D, Han X, Zhu L, Huang Z. Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma: A Systematic Review and Meta-analysis. JAMA Netw Open [Internet]. 2021 May 27 [cited 2022 Aug 3];4(5):219807. Available from: /pmc/articles/PMC8160596/
• 9. Jagasia M, Arora M, Flowers MED, Chao NJ, McCarthy PL, Cutler CS, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood [Internet]. 2012 Jan 5 [cited 2022 Aug 3];119(1):296–307. Available from: https://pubmed.ncbi.nlm.nih.gov/22010102/
• 10. Martin PJ, Counts GW, Appelbaum FR, Lee SJ, Sanders JE, Deeg HJ, et al. Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation. J Clin Oncol [Internet]. 2010 Feb 2 [cited 2022 Aug 3];28(6):1011. Available from: /pmc/articles/PMC2834427/
• 11. Gowda L, Seropian S. Life Expectancy After Allogeneic Stem Cell Transplant—In It for the Long Haul? JAMA Oncol [Internet]. 2021 Nov 1 [cited 2022 Sep 6];7(11):1611–3. Available from: https://jamanetwork.com/journals/jamaoncology/fullarticle/2783598
• 12. Cutler C, Antin JH. Peripheral Blood Stem Cells for Allogeneic Transplantation: A Review. Stem Cells [Internet]. 2001 Mar 1 [cited 2022 Sep 6];19(2):108–17. Available from: https://academic.oup.com/stmcls/article/19/2/108/6395487
• 13. Hilgendorf I, Greinix H, Halter JP, Lawitschka A, Bertz H, Wolff D. Long-Term Follow-up After Allogeneic Stem Cell Transplantation. Dtsch Arztebl Int [Internet]. 2015 Jan 23 [cited 2022 Aug 4];112(4):51. Available from: /pmc/articles/PMC4335490/
• 14. Penack O, Peczynski C, Mohty M, Yakoub-Agha I, Styczynski J, Montoto S, et al. How much has allogeneic stem cell transplant–related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Adv [Internet]. 2020 Dec 22 [cited 2022 Sep 6];4(24):6283–90. Available from: https://ashpublications.org/bloodadvances/article/4/24/6283/474704/How-much-has-allogeneic-stem-cell-transplant
• 15. Greco R, Labopin M, Badoglio M, Veys P, Silva JMF, Abinun M, et al. Allogeneic HSCT for autoimmune diseases: A retrospective study from the EBMT ADWP, IEWP, and PDWP working parties. Front Immunol. 2019;10(JULY):1570.
• 16. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant [Internet]. 2009 [cited 2022 Sep 7];15(10):1143–238. Available from: https://pubmed.ncbi.nlm.nih.gov/19747629/
• 17. Antin JH. Immune reconstitution: The major barrier to successful stem cell transplantation. Biol Blood Marrow Transplant [Internet]. 2005 Feb [cited 2022 Sep 7];11(2 SUPPL. 2):43–5. Available from: https://pubmed.ncbi.nlm.nih.gov/15682176/